ArticleJournal of nanobiotechnology2023
Biocompatible copper formate-based nanoparticles with strong antibacterial properties for wound healing.
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Nanoparticle-based approaches for bacterial detection and therapy.Applied microbiology and biotechnology · 2026Review
- Recent Progress and Morphological Distribution of Polydopamine-Based Biomaterials and Their Applications.Gels (Basel, Switzerland) · 2026Review
- A Photothermally Triggered Nanoplatform for Multidimensional Antibacterial Therapy and Accelerated Healing of Infected Wounds.International journal of nanomedicine · 2026Article
- Application and Advances of Cell Membrane-Coated Nanoparticles in Diabetic Wound Healing.International journal of nanomedicine · 2026Review
- Recent advances in phyto- and microorganisms-mediated synthesis of copper nanoparticles and their emerging applications in healthcare, environment, agriculture and food industry.Bioprocess and biosystems engineering · 2025Review
- Smart hybrid nanomaterials for chronic infections: microbiome-responsive and sustainable therapeutic platforms.Journal of nanobiotechnology · 2025Review
- Tailored brain metastatic tumor cells-derived apoptotic bodies ameliorate Alzheimer's disease by promoting microglia efferocytosis and neuroinflammation mitigation.Journal of nanobiotechnology · 2025Article
- Eco-friendly synthesis of Ag/CeORSC advances · 2025Article
- Copper stress shapes the dynamic behavior of amoebae and their associated bacteria.The ISME journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Copper-based antibacterial materials have emerged as a potential alternative for combating bacterial infections, which continue to pose significant health risks. Nevertheless, the use of copper-based nanoparticles as antibacterial agents has faced challenges due to their toxicity towards cells and tissues. To overcome this obstacle, we propose a new approach using a contact-active copper-based nanoparticles called polydopamine (PDA)-coated copper-amine (Cuf-TMB@PDA). The positively charged surface of Cuf-TMB@PDA enables efficient targeting of negatively charged bacteria, allowing controlled release of Cu(II) into the bacterial cell membrane. Moreover, Cuf-TMB@PDA exhibits similar ·OH signals as Cuf-TMB suspensions in previous work. In cytotoxicity assays conducted over 72 h, Cuf-TMB@PDA demonstrated an efficacy of 98.56%, while releasing lower levels of Cu(II) that were less harmful to cells, resulting in enhanced antimicrobial effects. These antimicrobial properties are attributed to the synergistic effects of charge-contact activity of PDA, controlled release of Cu(II), and free radicals. Subsequent in vivo experiments confirmed the strong antimicrobial potency of Cuf-TMB@PDA and its ability to promote wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.